Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Foghorn Therapeutics' Non Operating Income fell 4393.23% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 338.95%. This contributed to the annual value of $16.1 million for FY2024, which is 1719.68% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non Operating Income of $2.7 million as of Q3 2025, which was down 4393.23% from $3.2 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Non Operating Income high stood at $4.7 million for Q3 2024, and its period low was $144000.0 during Q1 2021.
  • Its 5-year average for Non Operating Income is $2.7 million, with a median of $3.2 million in 2025.
  • In the last 5 years, Foghorn Therapeutics' Non Operating Income surged by 951428.57% in 2021 and then tumbled by 4393.23% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Non Operating Income stood at $2.0 million in 2021, then skyrocketed by 48.59% to $3.0 million in 2022, then rose by 11.27% to $3.3 million in 2023, then skyrocketed by 34.87% to $4.5 million in 2024, then crashed by 41.09% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $3.2 million for Q2 2025, and $4.1 million during Q1 2025.